Past NextLevel Pharma Webinars

Although great strides have been made in predictive biomarkers in recent years, the industry is still far away from developing a complete and accurate range of safety tests. This webinar summarises what are the most innovative recent scientific developments and the most promising regulatory initiatives, as well as provides a platform for partnering amongst the pharma, biotech, diagnostics and academic sectors.

This webinar includes the following presentations:

• See, treat, cure: Biomarkers and imaging for drug development, diagnosis and treatment of diseases
• Multi-Scale in silico modeling of QT Prolongation Risk
• Demonstrating efficacy & safety at the same time: Potassium humate
• NTproBNP as risk marker for cardiovascular morbidity and mortality
• Safety Biomarkers: Inventing Our Way Out of the Problem?
• The QT Interval and Beyond: From pre-clinical prediction to clinical integration
• Combining Open Platform and Targeted Approaches for Biomarker Discovery and Verification
• QT Prolongation Biomarker for Risk Associated to Use of Antipsychotics, Example of Sertindole

The recordings of these webinars are available for purchase. For more details, please contact us at webinars(at)nextlevelpharma.com

Presentation 3 - John Jeremy Rice, Pd.D. - Multi-Scale in silico modeling of QT Prolongation Risk